Developer docs
API playgroundTry for free, no card

Search company profiles

MitoGenetics

Full company profile

uuid0003qhg

Namestring
MitoGenetics
Websiteurl
mitogenetics.com
Company typeenum
Private
Founded yearint
2010
Short descriptiontext

MitoGenetics is a privately held, small R&D company founded in 2010 in Ames, Iowa, focused on the regulation of mitochondrial disorders and diseases. It has no disclosed products, customers, or revenue, and its website is currently inactive.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmes, United States
HQ citystring
Ames
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
mitochondrial disease research, biotech R&D services, mitochondrial therapeutics, genetic disorder treatments, rare disease research
Industry3 codes
1Genetic & Genomic Rare Disease Therapeutics
CodeHLAIAIAAPrimaryYes
2Gene Therapy for Rare/Monogenic Diseases
CodeHLAAACAEPrimaryNo
3Neurogenetics & Rare Neurologic Diseases
CodeHLAKAIAOPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Mitochondrial Disease Research
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MitoGenetics is a research and development company focused on the regulation and treatment of mitochondrial disorders and diseases. The company conducts scientific investigation into mitochondrial biology with the goal of developing therapeutic interventions for conditions linked to mitochondrial dysfunction. No specific commercialized products, services, or platform offerings are documented in the available source material.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
1GenSight Biologics
TypeEmerging player
Description

Gene-therapy company with programs in LHON and other rare inherited mitochondrial-related ophthalmologic disorders. Comparable for genetic/mitochondrial disease overlap even though modality differs.

2Minovia Therapeutics
TypeEmerging player
Description

Cell-therapy company developing mitochondrial augmentation and transplantation approaches for mitochondrial diseases. Comparable emerging player in mitochondrial-disease therapeutics with a distinct modality.

3Mereo BioPharma Group
TypeEmerging player
Description

Clinical-stage rare-disease biotech whose portfolio has included mitochondrial disease candidates. Comparable as a small-cap rare-disease developer touching the mitochondrial therapeutic space.

4Pretzel Therapeutics
TypeDirect peer
Description

Developer of therapies for mitochondrial disorders, including approaches targeting mitochondrial DNA and metabolism. Directly comparable as a focused mitochondrial-disease therapeutic company.

5PTC Therapeutics (BioElectron / Edison Pharmaceuticals legacy)
TypeBroad incumbent
Description

Acquired BioElectron (formerly Edison Pharmaceuticals), which developed EPI-743/vatiquinone for mitochondrial disease. Broad rare-disease incumbent with overlapping mitochondrial-disease assets.

6Reneo Pharmaceuticals
TypeEmerging player
Description

Clinical-stage biotech developing therapies for rare mitochondrial diseases, including mavodelpar. Comparable as a focused rare-mitochondrial-disease R&D player.

7Abliva (formerly NeuroVive Pharmaceutical)
TypeDirect peer
Description

Swedish biotech developing therapies for primary mitochondrial disease, including complex I and II deficiencies. Direct peer operating in the same rare mitochondrial disease R&D space.

8Khondrion
TypeDirect peer
Description

Clinical-stage company developing small molecules for inherited mitochondrial diseases. Comparable in being a niche R&D biotech targeting mitochondrial disorders with similar patient populations.

9Astellas Pharma (Mitobridge acquisition)
TypeBroad incumbent
Description

Acquired Mitobridge in 2018, a mitochondrial-disease-focused biotech. Large pharmaceutical incumbent now holding mitochondrial R&D assets that were once a direct peer to MitoGenetics.

10Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage biotech developing therapies for mitochondrial dysfunction-related diseases (e.g., Barth syndrome, LHON). Direct peer to MitoGenetics by virtue of sharing mitochondrial disease as primary therapeutic focus.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MitoGenetics

Mitochondrial Disease Researchmitogenetics.com

MitoGenetics is a privately held, small R&D company founded in 2010 in Ames, Iowa, focused on the regulation of mitochondrial disorders and diseases. It has no disclosed products, customers, or revenue, and its website is currently inactive.

MitoGenetics firmographics

Firmographics
Name
MitoGenetics
Website
https://mitogenetics.com
Company type
Private
Founded year
2010
Operating status
Closed
Headcount range
11–50 employees
Short description
MitoGenetics is a privately held, small R&D company founded in 2010 in Ames, Iowa, focused on the regulation of mitochondrial disorders and diseases. It has no disclosed products, customers, or revenue, and its website is currently inactive.
Ownership category
akta.pro rank

MitoGenetics industry classification

Industry
Product category
Mitochondrial Disease Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
akta.pro secondary industries
Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

Keywords

  • Mitochondrial disease research
  • Biotech R&D services
  • Mitochondrial therapeutics
  • Genetic disorder treatments
  • Rare disease research

Where MitoGenetics is headquartered

Location

Headquarters

HQ city
Ames
HQ country
United States
HQ region
North America

Markets served

MitoGenetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

MitoGenetics product offering

Product offering

Core offering

MitoGenetics is a research and development company focused on the regulation and treatment of mitochondrial disorders and diseases. The company conducts scientific investigation into mitochondrial biology with the goal of developing therapeutic interventions for conditions linked to mitochondrial dysfunction. No specific commercialized products, services, or platform offerings are documented in the available source material.

Differentiator

Problem solved

Functional benefit

Companies that use MitoGenetics

Customer profile

Ideal customer profiles1 record

MitoGenetics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MitoGenetics competitors and assessment

Company assessment

Emerging players

  • GenSight Biologics: Gene-therapy company with programs in LHON and other rare inherited mitochondrial-related ophthalmologic disorders. Comparable for genetic/mitochondrial disease overlap even though modality differs.
  • Minovia Therapeutics: Cell-therapy company developing mitochondrial augmentation and transplantation approaches for mitochondrial diseases. Comparable emerging player in mitochondrial-disease therapeutics with a distinct modality.
  • Mereo BioPharma Group: Clinical-stage rare-disease biotech whose portfolio has included mitochondrial disease candidates. Comparable as a small-cap rare-disease developer touching the mitochondrial therapeutic space.
  • Reneo Pharmaceuticals: Clinical-stage biotech developing therapies for rare mitochondrial diseases, including mavodelpar. Comparable as a focused rare-mitochondrial-disease R&D player.

Direct peers

  • Pretzel Therapeutics: Developer of therapies for mitochondrial disorders, including approaches targeting mitochondrial DNA and metabolism. Directly comparable as a focused mitochondrial-disease therapeutic company.
  • Abliva (formerly NeuroVive Pharmaceutical): Swedish biotech developing therapies for primary mitochondrial disease, including complex I and II deficiencies. Direct peer operating in the same rare mitochondrial disease R&D space.
  • Khondrion: Clinical-stage company developing small molecules for inherited mitochondrial diseases. Comparable in being a niche R&D biotech targeting mitochondrial disorders with similar patient populations.
  • Stealth BioTherapeutics: Clinical-stage biotech developing therapies for mitochondrial dysfunction-related diseases (e.g., Barth syndrome, LHON). Direct peer to MitoGenetics by virtue of sharing mitochondrial disease as primary therapeutic focus.

Broad incumbents

Market position

Customer concentration

MitoGenetics social profiles

Digital presence

MitoGenetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MitoGenetics leadership team

Management profile

Number of profiles

Profiles2 records

MitoGenetics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MitoGenetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MitoGenetics

What does MitoGenetics do?

MitoGenetics is a research and development company focused on the regulation and treatment of mitochondrial disorders and diseases. The company conducts scientific investigation into mitochondrial biology with the goal of developing therapeutic interventions for conditions linked to mitochondrial dysfunction. No specific commercialized products, services, or platform offerings are documented in the available source material.

When was MitoGenetics founded?

MitoGenetics was founded in 2010. It employs 11 to 50 people.

Where is MitoGenetics based?

MitoGenetics is headquartered in Ames, United States, in the North America region.

Who are MitoGenetics's main competitors?

Emerging players on record are GenSight Biologics, Minovia Therapeutics, Mereo BioPharma Group and Reneo Pharmaceuticals. Direct peers are Pretzel Therapeutics, Abliva (formerly NeuroVive Pharmaceutical), Khondrion and Stealth BioTherapeutics. Broad incumbents are PTC Therapeutics (BioElectron / Edison Pharmaceuticals legacy) and Astellas Pharma (Mitobridge acquisition).

Does MitoGenetics have an API?

No public API is recorded for MitoGenetics.

What industry is MitoGenetics in?

MitoGenetics's product category is Mitochondrial Disease Research. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMitoGenetics to Present at 2015 BIO International Convention in PhiladelphiaMitoGenetics CEO Marcia Hendrickson will present the company's mitochondrial research at the 2015 BIO International Convention in Philadelphia on June 18. The presentation covers technology to regulate mitochondrial action, linked to diseases like diabetes and Alzheimer's. The company aims to develop products for longer, healthier lives.GlobeNewswireMitogenetics Chosen as a Presenter at the New York Innovation ShowcaseMitogenetics, LLC will present at the New York Innovation Showcase at SUNY Global Center on February 12. The company focuses on biomedical technology for mitochondrial dysfunction, which is linked to diseases like diabetes and Alzheimer's. Its research aims to develop therapeutic strategies and commercially viable products.GlobeNewswireMitogenetics Named One of the Top Innovators at the Annual New England Venture Summit in BostonMitogenetics, a South Dakota-based R&D company, was named one of 50 Top Innovators at the annual New England Venture Summit in Boston. The company will present its mitochondrial metabolism research to investors, aiming to generate visibility for its therapeutic strategies.GlobeNewswireMitogenetics Revolutionizes How People Manage DiseasesMitogenetics, a biomedical firm, is developing technology to regulate mitochondrial action, targeting diseases like diabetes and Alzheimer's. The company, founded in 2010, seeks fundraising to continue research and commercialize products. It was selected as one of the top 50 innovators at the New England Venture Summit.